Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Weekly Update for the Week Ending November 30, 2019

12/3/2019

 
Regulatory Update
 
The FDA approved voxelotor (Oxbryta, Global Blood Therapeutics) on 11/25/2019 for the treatment of sickle cell disease in patients 12 years and older. The drug had a PDUFA Date of 2/26/2020 and the FDA gave voxelotor Orphan Drug, Fast Track and Breakthrough Therapy Priority Designations.
 
The FDA granted a priority review for risdiplam (RG7916) targeting spinal muscular atrophy and set a PDUFA date for 5/24/2020. It is the only drug in our knowledge base targeting spinal muscular atrophy.
 
The FDA assigned pemigatinib a Priority Review for the treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements and assigned a PDUFA date of 5/30/2020.
 
CymaBay has terminated clinical trials evaluating seladelpar as a treatment for non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and put primary biliary cholangitis (PBC) studies on hold while it investigates atypical liver histological findings. There are eleven other investigational drugs in the Pharmaceutical Pipeline Tracker targeting NASH. 
 
Announced Research Updates
 
ChemoCentryx announced that in the 52-week, 331 patient, Phase III, ADVOCATE trial, 72.3% of patients treated with avacopan achieved remission [Birmingham Vasculitis Activity Score of zero and no glucocorticoid treatment for anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis for at least the preceding four weeks] at 26 weeks compared to 70.1% with corticosteroids. Additionally, 65.7% of avacopan patients remained in remission at 52 weeks compared to 54.9% with glucocorticoids.
 
Published Research Updates
 
In a 141 patient, Phase IIb, open-label trial, eryaspase plus either gemcitabine or FOLFOX treated patients had an overall survival (OS) of 6.2 months compared to 4.9 months with standard chemotherapy and progression-free survival (PFS) of 2 months compared to 1.8 months in patients with advanced pancreatic adenocarcinoma with low asparagine synthetase (ASNS) expression. In the overall population OS was 6 months compared to 4.4 months and PFS was 2 months compared to 1.6 months. 
 
AstraZeneca/Lilly’s lanabecestat 104-week, 2,218 patient, Phase II/III, AMARANTH trial and the 78-week, 1,722 patient, Phase III DAYBREAK-ALZ trial were both terminated early after an interim analysis failed to demonstrate an improvement or slowing in decline in the Alzheimer Disease Assessment Scale–cognitive subscale (ADAS-Cog13) compared to placebo in patients with early or mild Alzheimer’s disease.
 
In the 107-week, Phase III SAkuraSky trial, of 83 patients with neuromyelitis optica spectrum disorder (NMOSD) that were receiving immunosuppressive therapy, 80% of patients treated with satralizumab were relapse free compared to 57% of those given placebo.
 
In the 681 patient, Phase II/III PALM Trial, mortality was 33.5% after treatment with REGN-EB3, 35.1% after MAb114, 53.1% with remdesivir compared to 49.7% with porgaviximab (ZMapp) in patients infected with the Ebola virus.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.